JP2015522617A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522617A5
JP2015522617A5 JP2015523185A JP2015523185A JP2015522617A5 JP 2015522617 A5 JP2015522617 A5 JP 2015522617A5 JP 2015523185 A JP2015523185 A JP 2015523185A JP 2015523185 A JP2015523185 A JP 2015523185A JP 2015522617 A5 JP2015522617 A5 JP 2015522617A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
disease
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015523185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522617A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/050719 external-priority patent/WO2014014937A1/en
Publication of JP2015522617A publication Critical patent/JP2015522617A/ja
Publication of JP2015522617A5 publication Critical patent/JP2015522617A5/ja
Pending legal-status Critical Current

Links

JP2015523185A 2012-07-16 2013-07-16 タンパク質凝集の阻害剤としてのジ−およびトリ−ヘテロアリール誘導体 Pending JP2015522617A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672239P 2012-07-16 2012-07-16
US61/672,239 2012-07-16
PCT/US2013/050719 WO2014014937A1 (en) 2012-07-16 2013-07-16 Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation

Publications (2)

Publication Number Publication Date
JP2015522617A JP2015522617A (ja) 2015-08-06
JP2015522617A5 true JP2015522617A5 (enExample) 2016-09-01

Family

ID=49949212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015523185A Pending JP2015522617A (ja) 2012-07-16 2013-07-16 タンパク質凝集の阻害剤としてのジ−およびトリ−ヘテロアリール誘導体

Country Status (15)

Country Link
US (1) US9284309B2 (enExample)
EP (1) EP2872143B1 (enExample)
JP (1) JP2015522617A (enExample)
KR (1) KR20150031481A (enExample)
CN (1) CN104703604A (enExample)
AU (1) AU2013290361A1 (enExample)
BR (1) BR112015001096A2 (enExample)
CA (1) CA2877983A1 (enExample)
ES (1) ES2661394T3 (enExample)
HK (1) HK1210598A1 (enExample)
IL (1) IL236712A0 (enExample)
IN (1) IN2015DN01171A (enExample)
MX (1) MX2015000618A (enExample)
RU (1) RU2015104962A (enExample)
WO (1) WO2014014937A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57533B1 (sr) 2014-01-29 2018-10-31 Ucb Biopharma Sprl Heteroaril amidi kao inhibitori proteinske agregacije
WO2017020010A1 (en) 2015-07-29 2017-02-02 Neuropore Therapies, Inc. Bis-heteroaryl derivatives as modulators of protein aggregation
BR112019011932A2 (pt) 2017-01-26 2019-10-29 Ucb Biopharma Sprl derivados de bis-heteroarila como moduladores da agregação de proteína
ES2884145T3 (es) 2017-01-26 2021-12-10 UCB Biopharma SRL Derivados bicíclicos de bis-heteroarilo como moduladores de la agregación de proteínas
JP7100042B2 (ja) * 2017-01-26 2022-07-12 ユーシービー バイオファルマ エスアールエル タンパク質凝集のモジュレーターとしてのアルコキシビス-ヘテロアリール誘導体
US20190382346A1 (en) 2017-02-28 2019-12-19 Universitat Autonoma De Barcelona (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies
WO2019025424A1 (en) 2017-08-04 2019-02-07 Universitat Autonoma De Barcelona COMPOUNDS FOR TREATING SYNUCLEINOPATHIES
WO2019161917A1 (en) 2018-02-23 2019-08-29 Universitat Autonoma De Barcelona 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies
CN113683598B (zh) * 2020-05-18 2022-10-14 成都先导药物开发股份有限公司 一种免疫调节剂
WO2025223458A1 (zh) * 2024-04-23 2025-10-30 深圳众格生物科技有限公司 一种cyp11a1抑制剂、其制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782878B2 (en) 2000-02-05 2005-09-08 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
EP1317453B1 (en) * 2000-09-15 2006-08-09 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
WO2004014905A1 (en) * 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
TWI516487B (zh) * 2009-04-30 2016-01-11 葛蘭素集團有限公司 新穎化合物、其醫藥組合物及作為激酶活性抑制劑之用途
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2513090A1 (en) * 2009-12-16 2012-10-24 Neuropore Therapies, Inc. Compound suitable for the treatment of synucleopathies
US9198891B2 (en) * 2010-05-21 2015-12-01 New York University Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase

Similar Documents

Publication Publication Date Title
JP2015522617A5 (enExample)
JP2011088926A5 (enExample)
EP2872143B1 (en) Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
JP2018519323A5 (enExample)
IN2012DE00337A (enExample)
JP2011132222A5 (enExample)
JP2013542261A5 (enExample)
JP2014511892A5 (enExample)
JP2017526727A5 (enExample)
JP2011527331A5 (enExample)
CA2514384A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
JP2016511753A5 (enExample)
JP2012508734A5 (enExample)
JP2015535847A5 (enExample)
JP2012513416A5 (enExample)
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
JP2016513696A5 (enExample)
JP2017534665A5 (enExample)
JP2018537513A5 (enExample)
JP2016529235A5 (enExample)
JP2017534663A5 (enExample)
JP2019516739A5 (enExample)
NZ603108A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
RU2016104844A (ru) Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора
JP2011046708A5 (enExample)